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Abstract 
Background: Medicinal plants are a validated source for discovery of new leads and standardized herbal medicines. 
The aim of this study was to assess the activity of Vernonia amygdalina leaf extracts and isolated compounds against 
gametocytes and sporogonic stages of Plasmodium berghei and to validate the findings on field isolates of Plasmo-
dium falciparum.
Methods: Aqueous (Ver‑H2O) and ethanolic (Ver‑EtOH) leaf extracts were tested in vivo for activity against sexual and 
asexual blood stage P. berghei parasites. In vivo transmission blocking effects of Ver‑EtOH and Ver‑H2O were estimated 
by assessing P. berghei oocyst prevalence and density in Anopheles stephensi mosquitoes. Activity targeting early 
sporogonic stages (ESS), namely gametes, zygotes and ookinetes was assessed in vitro using P. berghei CTRPp.GFP 
strain. Bioassay guided fractionation was performed to characterize V. amygdalina fractions and molecules for anti‑ESS 
activity. Fractions active against ESS of the murine parasite were tested for ex vivo transmission blocking activity on P. 
falciparum field isolates. Cytotoxic effects of extracts and isolated compounds vernolide and vernodalol were evalu‑
ated on the human cell lines HCT116 and EA.hy926.
Results: Ver‑H2O reduced the P. berghei macrogametocyte density in mice by about 50% and Ver‑EtOH reduced P. 
berghei oocyst prevalence and density by 27 and 90%, respectively, in An. stephensi mosquitoes. Ver‑EtOH inhibited 
almost completely (>90%) ESS development in vitro at 50 μg/mL. At this concentration, four fractions obtained from 
the ethylacetate phase of the methanol extract displayed inhibitory activity >90% against ESS. Three tested frac‑
tions were also found active against field isolates of the human parasite P. falciparum, reducing oocyst prevalence in 
Anopheles coluzzii mosquitoes to one‑half and oocyst density to one‑fourth of controls. The molecules and fractions 
displayed considerable cytotoxicity on the two tested cell‑lines.
Conclusions: Vernonia amygdalina leaves contain molecules affecting multiple stages of Plasmodium, evidencing 
its potential for drug discovery. Chemical modification of the identified hit molecules, in particular vernodalol, could 
generate a library of druggable sesquiterpene lactones. The development of a multistage phytomedicine designed as 
preventive treatment to complement existing malaria control tools appears a challenging but feasible goal.
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Background
Despite intensive efforts to control malaria, the disease 
continues to be one of the greatest health problems faced 
by sub-Saharan African countries [1]. About 207 million 
clinical cases of malaria occurred in 2012 according to 
WHO estimates, maintaining its deplorable ranking as 
one of the top killer diseases [2]. Among the drugs cur-
rently used for malaria case management, artemisinin 
based combination therapy (ACT) [3] and primaquine 
[4] have impact on malaria transmission, by reducing the 
infectiousness of individuals to mosquitoes [5]. Clini-
cal evidence indicate that activity of artemisinin deriva-
tives is restricted to developing gametocytes, whereas 
primaquine is able to hit also the circulating mature 
gametocytes [6]. On the basis of the drugs’ respective 
activity profiles, the World Health Organization (WHO) 
recommends the addition of a single dose of primaquine 
to the ACT course for the management of uncompli-
cated Plasmodium falciparum malaria in areas threat-
ened by artemisinin resistance and/or in pre-elimination 
phase [7]. However, a viable alternative to primaquine 
is urgently needed, considering that this compound can 
provoke haemolytic anaemia in patients with glucose-
6-phosphate dehydrogenase deficiency [8]. Among the 
various available approaches, the exploration of empiri-
cally effective and chemically characterized anti-malarial 
plants represents a valid strategy for the discovery of new 
druggable compounds active against gametocytes and/
or sporogonic stages for the development of multi-stage 
combination medicines.
The connection between medicinal plants and success-
ful anti-malarial drug discovery dates back to 1820, time 
of quinine isolation from Cinchona bark [9] and contin-
ues to the current time, as witnessed by the development 
of various potent forms of ACT based on semisynthetic 
derivatives of artemisinin, a highly oxygenated sesquit-
erpene isolated as active principle of Artemisia annua 
[10]. The multistage activity of artemisinin derivatives 
on asexual blood stages and early gametocytes [11], has 
encouraged researchers to explore molecules of plant 
origin seeking not only activity on parasite stages devel-
oping in the vertebrate host, but also transmission block-
ing effects against the sporogonic stages developing in 
the mosquito vector. Recently, Lucantoni et  al. dem-
onstrated the in  vivo transmission blocking property of 
azadirachtin A enriched formulation (NeemAzal®) on 
Plasmodium berghei sporogonic development in Anoph-
eles stephensi mosquitoes [12]. When administered to 
mice at an azadirachtin A dose of 50  mg/kg, the com-
mercial Azadirachta indica seed extract [13] was found 
to completely block parasite development in the vector. 
Azadirachtin A has been shown to inhibit the formation 
of flagellate microgametes from microgametocytes with 
an IC50 of 3.5 µM [14], suggesting that microgametogen-
esis is a main target process of NeemAzal® transmis-
sion blocking action. The transmission blocking activity 
of this azadirachtin A rich neem product was recently 
confirmed in the human parasite P. falciparum by stud-
ies conducted in Burkina Faso on field isolates: gameto-
cytaemic blood supplemented with 70 ppm NeemAzal® 
and membrane fed to Anopheles coluzzii mosquitoes 
completely inhibited oocyst development and therefore 
infection in mosquitoes [15].
In many African countries, where malaria is endemic 
and in particular in rural areas where access to modern 
health care facilities is often hindered, traditional prac-
tices still play an important role. People give preference to 
the use of herbal remedies for several reasons including: 
easier access, lower cost, lack of awareness about mod-
ern drugs and belief that the use of traditional medicine 
is more safe and effective [16]. Currently, standardized 
anti-malarial phytomedicines are officially commercial-
ized in various malaria endemic countries over the world, 
namely China, Ghana, India, Mali and Burkina Faso. 
Among few such products for which clinical research 
has been conducted, encouraging results were obtained 
with Qing hao (Artemisia annua, Democratic Republic 
of Congo trials), Totaquina (Cinchona spp., Multicounty 
trials) and Phyto-laria (Cryptolepis sanguinolenta, Ghana 
trial) showing a parasite clearance at days 5–7 after treat-
ment of 70–100, 92–100 and 100%, respectively. These 
findings support their use as complementary tools to the 
conventional anti-malarial interventions or as alternative 
treatments in the absence of anti-malarial drugs [17].
In sub-Saharan countries, including Ethiopia, leaves of 
Vernonia amygdalina (Asteraceae) are used for the treat-
ment and prevention of malaria [18–21]. The anti-plas-
modial activity of this small shrub has been confirmed 
by several in  vitro [22–26] and in  vivo studies [27–30]. 
In a 4-day suppression test involving the administration 
of extracts immediately after mouse infection with P. 
berghei, a parasitaemia suppression of 67% was demon-
strated for ethanolic and methanolic extracts at doses of 
500 mg/kg (s.c.) and 1,000 mg/kg (p.o.), respectively [27, 
31], while an aqueous extract given to mice at 125  mg/
kg (p.o.) caused a 63% reduction of parasitaemia [28]. 
Employing the Rane test that involves the administra-
tion of extracts 3  days post-infection for the evaluation 
of curative efficacy, 200 mg/kg (i.p.) of aqueous [30] and 
500 mg/kg (s.c.) of ethanolic extract [27] suppressed 
parasitaemia by 74 and 71%, respectively. Interestingly, 
in a clinical trial examining the efficacy of an infusion of 
fresh V. amygdalina leaves in patients with uncompli-
cated falciparum malaria, an adequate clinical response 
was reported in 67% of the cases. However, complete 
parasite clearance occurred in only 32% of patients with 
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adequate clinical response, and among these, recrudes-
cence occurred in 71% [31].
Several secondary metabolites have been isolated and 
characterized from V. amygdalina leaves, such as sesquit-
erpene lactones [32–35], steroidal saponins (vernonio-
sides) [36], and flavonoids (luteolin and its glycosides) 
[37]. The class of sesquiterpene lactones is probably the 
most peculiar of this plant and it includes the highly 
oxygenated derivatives vernolide [32], vernodalol [32], 
vernodalinol [33], epivernodalol [34], vernodalin and 
vernomygdalin [35] and vernolepin [38]. Vernolide and 
vernodalin exhibited IC50 of 1.87 and 0.52 µg/mL, respec-
tively, against P. falciparum blood stages in vitro [39]. In 
another study, IC50 values of 8.4, 4.0, 4.2 and 11.4 µg/mL 
were obtained for vernolide, vernodalin, vernodalol and 
hydroxyvernolide, respectively [40].
On the basis of the above-illustrated broad knowledge 
available on V. amygdalina as an anti-malarial plant—
from its evidenced appreciable clinical efficacy to the 
partially characterized activity profile of some secondary 
metabolite—this plant has been selected as a valid candi-
date for investigation on potential inhibitors of Plasmo-
dium transmission stages.
The present study was aimed at characterizing the plant 
extracts for stage specific effects on gametocytes and 
sporogonic stages and at identifying the responsible com-
pounds through a bio-guided fractionation approach, 
then validating them on P. falciparum field isolates.
Methods
Plant material
Source
Vernonia amygdalina (Asteraceae) leaves were collected 
in the area of Karat town, located in Konso district, i.e., 
600  km south of Addis Ababa, Ethiopia, after the rainy 
season (October 2011). A leaf specimen was used for tax-
onomic identification, and authenticated by Mr. Melaku 
Wondafrash, a plant taxonomist. A voucher specimen 
was deposited (Solomon-0l) at the National Herbarium, 
Addis Ababa University, Ethiopia.
Preparation of extracts and fractions, and isolation 
of compounds
Vernonia amygdalina leaves were air-dried at room 
temperature in the shade and ground using a blender. 
Ground material (50 g) was macerated in ethanol (EtOH) 
for 24 h and filtered with filter paper (Whatman® no. 1). 
Ethanol was removed using a rotary evaporator at 40°C 
under reduced pressure. The extract was further concen-
trated by freeze drying and stored at −20°C until use. To 
prepare the aqueous extract (Ver-H2O), 50 g of ground V. 
amygdalina leaves were macerated in distilled water for 
24  h, then filtered and freeze dried. The percent yields 
of the aqueous and ethanol extractions were 14 and 8%, 
respectively.
To identify secondary metabolites responsible for 
transmission blocking activity, bio-guided fractiona-
tion was employed on a methanol (MeOH) extract of 
V. amygdalina leaves. Briefly, 450  g of leaf powder was 
macerated in 1 L of MeOH for 24 h for three times. The 
extract was then filtered and concentrated with rotary 
evaporator to obtain a dried MeOH extract (34.5 g, yield 
7.6%). A portion of this extract (27.9  g) was then parti-
tioned, first between water and ethyl acetate (EtOAc), 
and then between water and butanol (BuOH), to get 
the following phases: EtOAc (14.3 g), BuOH (4.9 g) and 
H2O (7.9  g). The EtOAc phase was selected for bioas-
say-guided fractionation. It was subjected to medium 
pressure liquid chromatography (MPLC) over a col-
umn packed with silica gel (230–400 mesh) and eluted 
with the following solvent gradient of increasing polar-
ity: n-hexane, to n-hexane:EtOAc (9:1), n-hexane:EtOAc 
(4:1), n-hexane:EtOAc (7:3), n-hexane:EtOAc (3:2), 
n-hexane:EtOAc (1:1), n-hexane:EtOAc (7:11), 
n-hexane:EtOAc (1:4), EtOAc, EtOAc:MeOH (1:1) and 
finally MeOH. A total of 40 eluates of 250 mL each were 
collected and combined on the basis of thin layer chro-
matography behaviour, to get 14 fractions which were 
then tested for anti-plasmodial activities in vitro.
The active fractions (fr. 11–14) were further purified by 
high performance liquid chromatography (HPLC) on a 
Knauer apparatus equipped with a refractive index detec-
tor and LUNA (5 µ, 250 × 4 mm Phenomenex) SI60 or 
Kinetex (2.6  µ, 100  ×  4.60  mm Phenomenex) C18 col-
umns. Fractions 11 and 12 were separated by HPLC (elu-
ent n-hexane/EtOAc 75:25, flow 0.8 mL/min) to get pure 
vernolide (125.3 mg). Fractions 13 and 14 were separated 
by HPLC (eluent n-hexane/EtOAc 1:1, flow 0.8 mL/min) 
to obtain pure vernodalol (108.5 mg). The chemical struc-
tures of vernolide and vernodalol are reported in Fig. 1. 
These compounds were identified by comparison of their 
spectral data, particularly NMR (1H NMR at 500  MHz 
and 13C NMR at 125 MHz measured on Varian INOVA 
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Fig. 1 Chemical structure of vernolide and vernodalol.
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spectrometers) with those published in the literature [41, 
42].
Plasmodium species
The following three strains of the murine malaria para-
site P. berghei were employed in transmission blocking 
experiments: (1) P. berghei ANKA strain (chloroquine 
and pyrimethamine-sensitive) [43, 44] for the assess-
ment of extracts’ activity against sexual and asexual blood 
stages in vivo; (2) P. berghei GFPcon (chloroquine-sensi-
tive and pyrimethamine-resistant) [43, 44] expressing a 
green fluorescent protein (GFP) at all life cycle stages, for 
the evaluation of extracts’ transmission blocking activity 
in  vivo; (3) P. berghei CTRPp.GFP strain (chloroquine-
sensitive and pyrimethamine-resistant), expressing GFP 
in zygotes and ookinetes [45, 46], for the assessment of 
extracts/fractions/molecules’ activity against the devel-
opment of early sporogonic stages (ESS) in vitro. The P. 
berghei CTRPP.GFP strain was kindly provided by Prof. 
R.E. Sinden from Imperial College of London, UK.
Plasmodium falciparum parasites isolated from indi-
viduals living in a hyperendemic area of Burkina Faso 
were employed to confirm transmission blocking effects 
on the human parasite species. The details of ethical 
approval are presented below in the ethical clearance 
section.
Mosquitoes
For the in  vivo transmission blocking studies with P. 
berghei, An. stephensi mosquitoes were used as experi-
mental vectors. The mosquito colony was maintained at 
a temperature of 30°C (±2°C), 12 h light/12 h dark cycle 
and 75–85% relative humidity in the insectary of the Uni-
versity of Camerino, Italy. Experiments were conducted 
with four to 5 days-old female mosquitoes that had been 
transferred to a 19°C chamber (temperature required for 
the development of P. berghei in the vector) 24 h prior to 
administration of infectious blood-meals.
For the ex vivo transmission blocking assay performed 
with P. falciparum field isolates, 4–5 days old An. coluzzii 
mosquitoes (previously classified as Anopheles gambiae 
form “M”) [47] were used. The colony, routinely reared in 
the insectary of the “Institut de Recherche en Sciences de 
la Santé”, Bobo-Dioulasso, Burkina Faso has been origi-
nally established from field collected mosquitoes in 2008.
Mice
Eight to ten weeks old BALB/c mice, weighing between 
18 and 25 g were used in this study. The mice were reared 
in the animal house of the University of Camerino at 
24°C, 14 h light/10 h dark cycle and 70% relative humid-
ity, fed on standard laboratory mice pellets (Muced-
ola s.r.l., Milano, Italy) and provided with tap water 
ad-libitum. Experimental animal rearing and handling 
were in compliance with the Italian Legislative Decree on 
the “use and protection of laboratory animals” (D. Lgs. 
116 of 10/27/92) and in full adherence with the Euro-
pean Directive 2010/63/UE. The mice were narcotized 
with a 1:1 mixture of xylazine and acepromazine at 13% 
inoculate in 100  μL phosphate buffered saline (PBS) 
i.p. before any mosquito bites procedures. At the end of 
experiments, carbon dioxide inhalation was the method 
of humane euthanasia used for mice.
Murine malaria model
The rodent in vivo malaria model consisting of P. berghei 
ANKA strain parasites, BALB/c mice as vertebrate hosts 
and An. stephensi mosquitoes as vectors, is routinely 
employed in drug discovery research for the assessment 
of in vivo transmission blocking and parasite suppression 
efficacy [12, 48–50] and has been validated by Coleman 
and colleagues [51]. This model was employed here to 
evaluate the in vivo transmission blocking and gametocy-
tocidal activity of V. amygdalina extracts.
Experimental procedures
Assessment of impact on parasite development in the 
vertebrate host and determination of gametocytocidal 
activity
Ethanolic (Ver-EtOH) and aqueous (Ver-H2O) extracts 
of V. amygdalina leaves at a dose of 500 mg/kg of mouse 
body weight were orally administered to experimen-
tal animals allocated to the treatment groups. This dos-
age corresponds approximately to the amount of the 
plant material taken up by malaria patients, according 
to the traditional medicine recipe [18]. For administra-
tion, Ver-EtOH was dissolved in distilled water contain-
ing 7.5% Tween 80 and 10% ethanol, while Ver-H2O was 
dissolved in distilled water only. Animals in the control 
group received a similar volume of the solvent used to 
dissolve the extracts. The daily dose of each extract was 
divided in two equal parts, and gavages were performed 
twice a day at an interval of 12 h, in a of 200 µL/mouse 
each. In each treatment and control group, six mice were 
used. Treatments were administered for a total of 9 days, 
starting 2 days before infection of the experimental mice 
through the bites of 12–14 Anopheles females harbour-
ing sporozoites in their salivary glands [52]. On day 7 
post-infection, thin blood smears were prepared and 
stained with 7.5% Giemsa solution (Merck, Germany) for 
50 min. Smears were examined under a microscope with 
oil immersion objective (100×) to assess parasitaemia (all 
stages) and gametocyte densities. Plasmodium berghei 
infected red blood cells (RBCs) were counted out of 100 
total RBCs on three microscopic fields to determine par-
asitaemia. For low parasitaemias (<1%), up to 4,000 total 
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erythrocytes have been counted. To estimate gametocy-
taemia, microgametocytes and macrogametocytes were 
counted in at least 16 fields against 2,500 infected RBCs.
Assessment of transmission blocking activity in vivo
The in  vivo transmission blocking effect of V. amygdalina 
was estimated by determining oocyst prevalence and density 
in mosquitoes fed on extract-treated gametocytaemic mice 
[12]. Briefly, mice were inoculated with 107 P. berghei GFP-
con-infected red blood cells (RBCs) through the intraperito-
neal (i.p.) route. On day 3 post-infection, animals allocated to 
the treatment groups were treated i.p. with 500 and 100 mg/
kg (maximum tolerable dose) of Ver-H2O and Ver-EtOH, 
respectively, while control animals received 200  µL of the 
solvents used to dissolve the extracts. On day 4 post-infec-
tion, the treatment was repeated 1 h before the exposure of 
the mice to mosquitoes (day 4 gametocytes yield consistently 
high mosquito infections in this model). Mice were anaesthe-
tized and kept on top of mosquito cages containing 150–200 
An. stephensi females for 1 h. Unfed females were removed 
the following day. On day 10/11 after the blood meal, 17–34 
mosquitoes from each cage were dissected. Oocyst preva-
lence and density were assessed by counting the number of 
green fluorescent oocysts on mosquito mid-guts under a 
fluorescence microscope (ZEISS Axio Observer Z1, FITC fil-
ter 9) (Fig. 2). Oocyst density was determined by calculating 
the geometric mean of the number of oocysts recorded on 
oocyst positive mosquitoes [53].
Geometric mean = antilog
([∑n
i=1
logx
]
/n
)
,
where n = Number of oocyst positive mosquitoes,
x = Oocyst number per mosquito
 
The percent reduction of oocyst density in treatment 
groups was calculated as follows:
The experiment was conducted in triplicate, using for 
each treatment group three mice and for each mouse one 
cage of mosquitoes.
Evaluation of effects on early sporogonic stages in vitro
The impact of V. amygdalina on the development of ESS 
was evaluated according to the method described by 
Delves et al. [54] with slight modifications.
Source of gametocytes
To stimulate erythropoiesis, mice were treated with 
phenylhydrazine (120  mg/kg i.p.) 4  days before being 
infected with P. berghei CTRPp.GFP through i.p. injec-
tion of 107 infected RBCs. Gametocytaemia was checked 
4  days post-infection by microscopic examination of 
thin blood films and the maturity of microgametocytes 
verified by testing their capacity to generate flagellate 
microgametes in an exflagellation assay. In brief, for each 
gametocytaemic mouse a drop of tail blood was diluted 
at a ratio of about 1:25 in exflagellation medium (RPMI 
1640 containing 25 mM HEPES, 25 mM sodium bicarbo-
nate, 50  mg/L hypoxanthine, 100 μM xanthurenic acid, 
pH 7.6–8). Then, 8 µL of the diluted blood sample were 
placed centrally on a hand-made chamber consisting of 
a microscope slide as a base, two cover slips placed on 
it laterally as spacers, and a third one put on the top to 
close the chamber. To avoid drying out of the 8 µL blood 
droplet, the chamber was sealed with a mixture of Vase-
line and Tween 80 (approximately 1:2 ratio). After 20 min 
incubation at 19°C, slides were examined for exflagella-
tion under the microscope (400× magnification) (Fig. 3). 
Mice with abundant exflagellation centres (more than 3 
per 1,000 red blood cells) were selected for the ookinete 
development assay.
Ookinete development assay (ODA)
This assay allows the assessment of inhibition of the early 
sporogonic development in the vector, including male 
and female gametogenesis, zygote formation and ooki-
nete maturation. To simulate the physicochemical con-
ditions of the mosquito midgut environment in  vitro, 
180  µL of ookinete medium (exflagellation medium 
supplemented with 20% heat inactivated foetal bovine 
serum), 10 U/mL penicillin and 10 µg/mL streptomycin 
were added to a 96-well microplate (Nunc, Denmark). 
Percent reduction of oocyst density
=
(
1−
average oocyst density in treated group
average oocyst density in control group
)
× 100
Fig. 2 Plasmodium berghei GFPcon oocysts on mosquito mid‑gut, 
10 days after infection.
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Dimethyl sulfoxide (DMSO, a solvent dissolve extracts/
molecules) and PBS a solvent for the aqueous extract 
were used as controls, at a maximum concentration 
of 0.2%. Twenty microlitre of diluted V. amygdalina 
extracts, fractions or molecules were then added to the 
microplate wells to obtain the desired test concentra-
tions (3–50  µg/mL). Then, 20  µL of blood obtained 
from gametocytaemic mice by cardiac puncture were 
transferred to the test microplates and mixed swiftly. 
The plates were then incubated at 19°C for 40 h. At the 
end of the incubation, the plate contents was mixed and 
10 µL of cell suspension from each well were withdrawn, 
diluted with serum-free medium at a ratio of 1:25–1:50 
and transferred to a fresh 96-well microplate. This dilu-
tion step allowed to obtain—after cell settlement—a RBC 
monolayer, allowing accurate microscopic counts. GFP-
expressing zygotes and ookinetes were visualized using 
a fluorescence microscope (400× magnification) (Fig. 4) 
and quantified with the help of an ocular grid. ESS counts 
were performed in a series of fields along the well diame-
ter. Percent inhibition of ESS development was calculated 
as follows:
 
Percent inhibition of ESS development
=
(
1−
Mean ESS count in test wells
Mean ESS count in solvent control wells
)
× 100
Each substance was tested in 3–6 replicate wells and 
experiments were repeated at least twice.
Extracts/molecules demonstrating a >80% inhibition 
at 50  µg/mL were dose ranged to determine the IC50 
values.
Evaluation of effects on exflagellation of male gametocytes 
in vitro
Extracts/molecules found active in the ODA were tested 
in an exflagellation assay to assess stage-specific effects 
on male gametogenesis. The exflagellation assay was car-
ried out according to the protocol illustrated above [55, 
56]. Mice were treated with phenylhydrazine and infected 
with P. berghei ANKA. On day 4 post-infection, 5 μL tail 
blood were collected and resuspended in 140 μL exflagel-
lation medium containing 50 μg/mL Ver-EtOH or 50 μM 
vernodalol, dissolved in DMSO to a maximum DMSO 
concentration of 0.2%. DMSO and azadirachtin A were 
used as negative and positive controls, respectively [14]. 
The number of exflagellation centres per 1,000 RBCs, as 
an index of microgametogenesis [57, 58], were counted 
under the microscope (400× magnification), 20 min after 
mounting the slide chambers. For each concentration 
of test extract/molecule triplicate slides were counted 
(Fig. 3).
Fig. 3 Exflagellation centres, vibrating accumulations of red blood 
cells attaching to microgametocytes with extruding motile, flagellate 
gametes. Photograph was taken after incubation of gametocytaemic 
blood in exflagellation medium for 20 min. Fig. 4 Early sporogonic stages: spherical zygote (white arrow) and 
elongated ookinetes (red arrows).
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Assessment of effects on the feeding capacity of Anopheles 
stephensi
The impact of Ver-EtOH on An. stephensi blood feeding 
was assessed to evaluate whether a reduction in mosquito 
infection in the in  vivo transmission blocking experi-
ment might be the result of decreased blood intake and 
hence ingestion of a reduced number of gametocytes. 
Feeding capacity was estimated by measuring the hae-
matin content in the rectal fluid excreted by female mos-
quitoes during blood feeding. Briefly, narcotized mice, 
treated with 100  mg/kg extract or solvent control (i.p.) 
1  h before, were placed on top of mosquito cages and 
the rectal fluid from feeding mosquitoes was collected in 
plastic Petri dishes (15  cm diameter), previously placed 
inside the mosquito cage. The content of each Petri dish 
was then dissolved in 20 mL of 0.1 M NaOH and incu-
bated overnight to allow for the conversion of haemo-
globin to haematin [59]. To remove debris, the mixture 
was centrifuged at 13,000  rpm for 10  min. Supernatant 
samples were then serially diluted twofold in a 96-well 
microplate and the absorbance was measured at 392 nm 
wavelength using a FLUOstar Omega microplate reader 
(BMG Labtech, Germany). Commercial haemin (Sigma-
Aldrich) was dissolved in 0.1 M NaOH in order to derive 
haematin solutions [60] for the preparation of a calibra-
tion curve. The concentration of haematin in the diluted 
samples was then determined by extrapolating the optical 
density values onto the standard curve.
Cytotoxicity assessment
General cell toxic effects of V. amygdalina constitu-
ents were assessed on human colon carcinoma cell line 
HCT116 and human endothelial cell line (EA.hy926). 
HCT116 was cultured in RPMI1640 medium with 
2  mM  l-glutamine, 100  IU/mL penicillin, 100  μg/mL 
streptomycin, and supplemented with 10% heat-inacti-
vated foetal bovine serum (HI-FBS; PAA Laboratories 
GmbH, Austria). EA.hy926 was cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 2  mM  l-glu-
tamine, 100  IU/mL penicillin, 100  µg/mL streptomycin 
and supplemented with 10% HI-FBS. Cells were cultured 
in a humidified atmosphere at 37°C in presence of 5% CO2.
The cytotoxic activity of extracts, fractions and pure 
compounds from V. amygdalina leaves was measured by 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay [61]. Briefly, 100  µL aliquots of 
cell suspensions were plated at a density of 2 × 104 cells/
mL in flat-bottomed 96-well microplates (Falcon, Becton 
Dickinson Labware, USA). After 24 h, cells were exposed 
to compounds, fractions and extracts at concentrations 
ranging from 0.78 to 200  μg/mL, or 0.1% DMSO as 
control. Cell cultures were incubated at standard condi-
tions for 72  h. At the end of the incubation, 10  µL/well 
of MTT (5  mg/mL in phosphate-buffered saline) were 
added to the plates, and these were further incubated 
for 4  h at 37°C. Formazan crystals, produced by viable 
cells, were dissolved in 100 μL of DMSO after removal 
of the medium from the wells. Absorbance was meas-
ured at 540  nm using a FLUOstar Omega microplate 
reader. Cytotoxicity was expressed as the concentra-
tion of extracts, fractions or pure compounds inhibiting 
cell growth by 50% (IC50). The selectivity index (SI) was 
derived by dividing the IC50 value for mammalian cells by 
that obtained in the ODA against ESS.
Assessment of transmission blocking activity 
on Plasmodium falciparum field isolates
Study site and recruitment of gametocyte carriers
The study was conducted in the area of Bobo-Dioulasso 
(Southwest Burkina Faso) during the high transmission 
season (September to October) in 2013 [15]. Gameto-
cyte positive blood samples for the direct membrane-
feeding assay (DMFA) were obtained from children aged 
5–11  years. Totally 875 children were examined during 
seven screening events. At each survey the children were 
clinically examined for the presence of chronic diseases 
and acute infections including signs of severe malaria. 
Finger-prick blood was collected for the preparation of 
thick smears and measurement of haemoglobin using 
Hemocue (AB Leo Diagnostics, Helsingborg, Sweden). 
Medication history, namely use of anti-malarial drugs 
during the last two weeks and hypersensitivity history, 
was recorded.
Giemsa-stained thick smears were examined at the 
laboratory of the “Institut de Recherche en Sciences de 
la Santé” (IRSS) on the same day. On each slide 100 fields 
were screened for the presence of Plasmodium para-
sites. On positive slides, asexual parasite and gametocyte 
numbers were determined per 200 and 1,000 leukocytes, 
respectively. Gametocytaemia and parasitaemia were 
then expressed as gametocytes/µL and total number of 
parasites/µL of blood, referring to 8,000  leukocytes/µL 
of blood [15]. Asymptomatic children with P. falcipa-
rum gametocytaemia ≥40 gametocytes/µL, parasitaemia 
≤1,200 parasites/µL and negative for other Plasmodium 
species were selected as blood donors for the DMFA 
scheduled for the following day.
All parasitologically confirmed malaria cases during 
screening for the identification of gametocyte donors 
were treated with a combination of artesunate (4 mg/kg 
body weight) and amodiaquine (10 mg/kg body weight), 
once daily for 3 days.
Test fractions
Fractions 11, 13, and 14 from the EtOAc phase were 
selected based on anti-ESS activity obtained in the ODA 
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with P.  berghei and were tested for transmission-block-
ing activity on P. falciparum isolates.
Direct membrane feeding assay
The assay involving P.  falciparum gametocytaemic blood 
from volunteer individuals and An. coluzzii mosquitoes 
[15] has been validated by Bousema and colleagues for the 
assessment of transmission blocking interventions [62]. 
Batches of about 50 female An. coluzzii mosquitoes were 
housed in cardboard cups covered with mesh nettings. 
Aliquots of 500  μL gametocytaemic blood containing 
fractions 11, 13 and 14 from V. amygdalina at a concen-
tration of 100  μg/mL were placed in glass feeders and 
mosquitoes were allowed to feed for 45 min. Unfed mos-
quitoes were discarded. On day 7 after membrane feeding, 
all surviving mosquitoes were examined for prevalence 
and density of oocysts. Mosquito midguts were dissected 
and mounted in PBS containing 1% mercurochrome as 
an oocyst stain. Geometric means of oocyst densities [53] 
were calculated considering positive mosquitoes only.
Ethical clearance
The field study involving venous blood collection from 
children infected with P. falciparum was approved by the 
Ethical Committee of the Centre Muraz and filed under 
the registration number N/Ref. 003-2009/CE-CM. Par-
ents or guardians provided written informed consent 
before children were enrolled into the blood sample 
collection.
The experiments conducted with mice in the ani-
mal rearing facilities of the University of Camerino had 
been examined by the Ethical Committee of the Univer-
sity (COMITATO ETICO DI ATENEO Protezione degli 
Animali utilizzati a fini sperimentali o altri fini scienti-
fici CEAPA) to be compliant with the Italian Legislative 
Decree on the “use and protection of laboratory animals” 
(D. Lgs. 116 of 10/27/92, paragraph 7) and had been 
approved by the Counsel of the School of Pharmacy, Uni-
versity of Camerino.
Statistical analyses
Excel 2007 spreadsheet (Microsoft office) and GraphPad 
Prism 6 statistical software (GraphPad Software, San 
Diego, CA, USA) were used for data analysis. Normally 
distributed data, namely gametocyte densities, haematin 
values, ESS counts and derived % inhibition values, were 
expressed as arithmetic means and 95% confidence inter-
vals (95% CI), whereas oocyst densities among infected 
mosquitoes were expressed as geometric means and 95% 
CI. The independent samples Student’s t-test was used to 
compare means and Fisher’s exact test to compare cat-
egorical data. The a priori statistical significance level (α) 
was set at 0.05.
Results
Gametocytocidal activity in vivo
On day 7 after exposure to infectious mosquito bites, 
mice treated orally with 500 mg/kg Ver-H2O for 9 days 
showed a 46.8 and 45.4% reduction in macrogameto-
cyte densities in two independent experiments. In the 
first one, mean counts of 48 and 25.5 macrogameto-
cytes/2,500 infected red blood cells (iRBCs) were 
recorded in control and treatment mice, respectively, 
and respective counts of 42.7 and 23.3 (p  <  0.05) 
were obtained in the replicate experiment. Ver-H2O 
appeared to affect also microgametocytes but a sig-
nificant reduction of male sexual forms (p < 0.05) was 
observed only in one of the two experiments. Ver-
EtOH treatment at 500  mg/kg did not impact sig-
nificantly on macro- or microgametocyte densities 
(Table 1).
Examining the same slides of the two experiments for 
asexual forms, Ver-EtOH was found to reduce parasitae-
mia by 59.2% (95% CI 52.6–65.7%). Parasitaemia in the 
groups treated with Ver-EtOH amounted 3.6 and 8.7% in 
the control groups (p  <  0.05). Ver-H2O reduced parasi-
taemia by 33.6% (95% CI 26.7–40.2%), parasitaemia val-
ues of 5.8 and 8.7% were recorded in the treatment and 
control groups, respectively (p < 0.05).
Table 1 Effect of Vernonia amygdalina leaf extracts on Plasmodium berghei gametocyte densities
Data are presented as arithmetic means with 95% confidence intervals (95% CI).
IRBCs infected red blood cells, Ver-EtOH ethanolic V. amygdalina leaf extract, Ver-H2O aqueous V. amygdalina leaf extract *p < 0.05 with respect to their control.
a Numbers 1 and 2 refer to the two replicate experiments each involving treatment and control groups consisting of six mice each.
Treatment groups Experimenta Microgametocytes per  
2,500 IRBCs (95% CI)
Macrogametocyte per 
2,500 IRBCs (95% CI)
Ver‑EtOH 1 6.7 (5.4–8.0) 40.3 (35.9–44.7)
2 6.8 (5.6–8.0) 38.4 (32–44.8)
Ver‑H2O 1 5.5 (4.9–6.1) 25.5 (22.8–28.2)*
2 5.3 (4.9–5.7)* 23.3 (20.7–26.0)*
Control 1 7.2 (5.1–9.3) 48 (34.7–61.3)
2 8.5 (6.1–10.9) 41.7 (33.6–49.7)
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Transmission blocking activity in vivo
Both, Ver-EtOH and Ver-H2O, when administered to 
mosquitoes through a blood meal on treated gametocy-
taemic mice, impacted on the vector infection. Ver-H2O 
reduced oocyst density by 54.7% (95% CI 35.3–72.1). The 
mean number of oocysts amounted 266 in control mos-
quitoes fed on solvent-treated mice and 123 in the mos-
quitoes fed on mice treated with Ver-H2O (p < 0.05). The 
number of uninfected mosquitoes (infection prevalence) 
was similar in Ver-H2O and control mosquitoes (Table 2). 
Ver-EtOH reduced both infection prevalence and inten-
sity. The prevalence amounted 71.4% (95% CI 61.3–
81.5%) in mosquitoes fed on Ver-EtOH, compared with 
97.6% (95% CI 94.4–100.9%) in controls, corresponding 
to a significant reduction of 27% (p < 0.05). Among the 
infected mosquitoes, the mean oocyst density was 374 in 
control mosquitoes versus 37 in Ver-EtOH treated mos-
quitoes, resulting in a 90% reduction of oocyst numbers 
(95% CI 83.2–96.8%; p < 0.05) (Table 2).
In Ver-EtOH experiments, the feeding capacity of treat-
ment and control mosquitoes was estimated by meas-
uring the amount of haematin excreted with the rectal 
fluid. Mosquitoes offered a blood meal on mice treated 
with Ver-EtOH took slightly but not significantly less 
blood compared with mosquitoes fed on control mice. 
The mean amount of haematin was 5  µg per mosquito 
(95% CI 4.34–5.66 µg) in those having fed on Ver-EtOH 
treated mice versus 6.2  µg per mosquito (95% CI 5.2–
7.2  µg) in the control group (p  =  0.13). Similar results 
were obtained in a replicate experiment, yielding a value 
of 8.6 µg per fed mosquito (95% CI 7.53–9.67 µg) in the 
extract-exposed group versus 11.1 µg per mosquito (95% 
CI 9.6–12.6  µg) in controls (p =  0.06). Five microgram 
approximately corresponds to the haematin content of 
1 µL blood.
Impact on the development of early sporogonic stages 
in vitro
Ethanolic and aqueous extracts
The two extracts found active in our in vivo transmission 
blocking study (Ver-EtOH and Ver-H2O) were investi-
gated in  vitro for inhibition of ESS, hypothesizing that 
the ESS developing in the mosquito midgut in the first 
24 h after blood ingestion, are likely targets for the bio-
active extract metabolites. Ver-EtOH tested at the initial 
screening dose of 50  μg/mL was found to inhibit ESS 
development by 81.3–96.2%, while the aqueous extract 
showed no inhibitory activity (Table 3).
Dose range experiments performed with Ver-EtOH 
allowed us to determine an IC50 value of 15.4  µg/mL 
(95% CI 12.7–18.8  µg/mL). Enumerating zygotes and 
ookinetes separately, the proportion of ookinetes, which 
include zygotes initiating elongation and developing to 
fully mature (“banana shaped”) ookinetes, was found 
to be reduced at the highest Ver-EtOH test concentra-
tion. In control wells 90–98 % of zygotes were recorded 
to undergo ookinete development, whereas in those to 
which Ver-EtOH was added at50 µg/mL only about one 
fifth to one half of total ESS presented elongated forms 
(Fig. 5).
Table 2 Effect of  ethanolic and  aqueous leaf extracts of  Vernonia amygdalina on  Plasmodium berghei oocyst develop-
ment in Anopheles stephensi mosquitoes
The oocyst densities (geometric mean of oocysts/mosquito) were calculated on oocyst positive mosquitoes only.
Ver-EtOH ethanolic V. amygdalina leaf extract, Ver-H2O aqueous V. amygdalina leaf extract, Sol-EtOH and Sol-H2O are solvent controls for the ethanolic and aqueous 
extract, respectively.
* Oocyst density in extract treated groups significantly different with respect to the solvent controls; P < 0.05.
a Each number represents one gametocytaemic treatment or control mouse used for the infection of a separate batch of mosquitoes (100–150 females per mouse).
Group Mouse IDa Prevalence of infected mosquitoes 
(infected/total examined)
Oocyst density by mouse  
replicate (95% CI)
Oocyst density by treatment 
group (95% CI)
Ver‑EtOH 1 76.9 (20/26) 27 (13–57) 37 (26–53)*
2 29.4 (5/17) 12 (5–28)
3 88.2 (30/34) 56 (32–96)
Sol‑EtOH 4 100 (34/34) 417 (297–585) 374 (297–467)
5 96.4 (27/28) 439 (319–605)
6 95.7 (22/23) 260 (152–447)
Ver‑H2O 7 100 (20/20) 72 (45–103) 123 (83–149)*
8 100 (20/20) 151 (101–161)
9 100 (20/20) 143 (104–182)
Sol‑H2O 10 100 (20/20) 272 (225–319) 266 (200–300)
11 100 (20/20) 242 (186–298)
12 100 (20/20) 237 (190–284)
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Phases and fractions
Following the congruent results emerging from the 
in  vitro and in  vivo transmission blocking experiments 
with the Ver-EtOH, bioassay guided fractionation studies 
were undertaken to identify the molecule(s) responsible 
for the observed activity against EES.
Ver-MeOH (for the procedures of chemical analy-
sis, MeOH was preferred to EtOH as extraction solvent, 
since they have practically identical extracting efficiency) 
revealed moderate in vitro activity against ESS, at the ini-
tial screening dose of 50 µg/mL, consisting in a 51–68.3% 
ESS development inhibition (Table 4). The BuOH phase 
separated from Ver-MeOH displayed higher inhibitory 
activity (>86%). This fraction, however, was found to be 
cytotoxic to RBCs provoking evident haemolysis at this 
dosage. The EtOAc phase displayed an inhibition range 
of 58.3–79.1%, whereas the water phase showed poorly 
reproducible effects (Table  4). Based on these results, 
the EtOAc phase was selected for further fractionation, 
whereas the BuOH and H2O phases were not considered 
for further study due to cytotoxicity, for the former, and 
doubts on the specificity of the effects displayed by the 
latter. The EtOAc phase was subjected to medium pres-
sure liquid chromatography (MPLC) and 14 fractions 
were obtained. Based on proton-NMR preliminary analy-
sis, four fractions containing fatty acids and/or triglycer-
ides were not considered for testing, while ten fractions 
were screened in  vitro for impact on ESS development. 
Fractions 2, 3, 5, 8, 9, and 10 did not exhibit relevant 
reproducible activity at 50  μg/mL, whereas fractions 
11 to 14 caused almost complete ESS inhibition (>90%). 
These fractions were eluted with mobile phases of differ-
ent polarity, namely fr 11 [n-hexane:EtOAc (1:1 to 7:11)], 
fr 12 [n-hexane:EtOAc (7:11 to 1:4)], fr 13 [EtOAc] and fr 
14 [EtOAc:MeOH (1:1)] (Table 5).
Transmission blocking activity of Vernonia amygdalina leaf 
fractions against Plasmodium falciparum field isolates
Fractions demonstrating activity against P. berghei ESS in 
the ookinete development assay were tested for confir-
mation of transmission blocking activity on field isolates 
of the human malaria parasite P. falciparum. All fractions 
affected the sporogonic development of P.  falciparum in 
Table 3 Impact of Vernonia amygdalina leaf extracts on the development of early sporogonic stages in vitro
Ver-EtOH and Ver-H2O were tested at 50 µg/mL.
Data are presented as mean early sporogonic stages (ESS) counts calculated from triplicate wells and percentages of ESS inhibition referred to solvent controls. Both 
parameters are presented with 95% confidence intervals (95% CI).
Ver-EtOH ethanolic V. amygdalina leaf extract, Ver-H2O aqueous V. amygdalina leaf extract, Sol-EtOH (dimethyl sulfoxide at 0.2%) and Sol-H2O (phosphate buffered 
saline) are solvent controls for the ethanolic and aqueous extract, respectively.
a Each number represents one experiment conducted with gametocytaemic blood from a different mouse.
b Mean ESS counts are rounded to the nearest whole numbers.
Test agents Experimenta Mean ESS counts (95% CI)b Percentage inhibition 
of ESS (95% CI)
Ver‑EtOH 1 53 (46–60) 81.3 (79.1–83.7)
2 11 (3–19) 96.2 (93.4–99.1)
3 18 (15–20) 87.5 (85.8–89,14)
4 45 (41–50) 88 (86.7–89.4)
Sol‑EtOH 1 285 (239–332)
2 283 (261–306)
3 141 (120–163)
4 378 (310–446)
Ver‑H2O 5 51 (42–60) 14 (5–23.1)
6 23 (14–32) 38.7 (14.2–63.3)
Sol‑H2O 5 59 (51–68)
6 37 (32–42)
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Fig. 5 Proportion of mature ookinetes with respect to total early 
sporogonic stages. The test was conducted using ethanolic Verno-
nia amygdalina leaf extract (Ver‑EtOH) at different concentration 
and solvent control (dimethyl sulfoxide). Each bar in the graph refers 
to readings from 3 and 6 microplate wells in experiment 1 and 2, 
respectively.
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An. coluzzii mosquitoes when administered to females by 
membrane feeding, at 100 µg/mL.
The number of infected mosquitoes was reduced 
upon treatment with fraction 11, 13 and 14, however 
prevalence values varied conspicuously across replicate 
experiments (Table  6). In control mosquitoes fed on 
DMSO-supplemented gametocytaemic blood, oocyst 
prevalence ranged from 30 to 50%. Fraction 13 was found 
to block mosquito infection in one replicate experiment 
and to significantly reduce oocyst prevalence to 6.5 and 
8.3% in the other two. A significant reduction in oocyst 
prevalence was also recorded with fraction 11 and 14 in 
two out of the three replicate experiments. Fraction 11 
inhibited oocyst development completely in one occa-
sion (Table 6; Fig. 6). Oocyst density, assessed on positive 
midguts only, was reduced overall by about a half in 
treated mosquitoes (Table 6; Fig. 6).
Activity of pure compounds from Vernonia amygdalina 
molecules against Plasmodium berghei early sporogonic 
stages
HPLC purification and subsequent NMR-based struc-
tural characterization of the constituents of the active 
fractions allowed the identification of the sesquiterpene 
lactone vernolide as the major compound of fraction 11 
and 12 and vernodalol (Fig.  1) of fractions 13 and 14. 
The two compounds were tested in the ODA at 50 μM, 
revealing vernodalol as the most active molecule, inhibit-
ing ESS development by 70–90%. Vernolide showed weak 
and variable inhibitory activity (Table  7). Dose range 
Table 4 Impact of Vernonia amygdalina leaf methanolic extract and derived phases on the development of early sporo-
gonic stages
Methanolic V. amygdalina leaf extract and its butanol, ethylacetate and water phases were tested at 50 µg/mL.
Data are presented as mean counts of early sporogonic stages (ESS) calculated from triplicate wells and percentages of ESS inhibition referred to solvent control. Both 
parameters are presented with 95% confidence intervals (95% CI).
Ver-MeOH methanolic extract of V. amygdalina leaves.
a Each number represents one experiment conducted with gametocytaemic blood from a different mouse.
b Mean ESS counts are rounded to the nearest whole number.
Test agents Experimenta Mean ESS (95% CI)b Percentage inhibition 
of ESS (95% CI)
Ver‑MeOH 1 13 (9–18) 51.0 (34.2–67.8)
2 4 (3–6) 68.3 (58.7–77.9)
3 41 (34–47) 57.5 (50.6–64.4)
4 105 (92–118) 51.9 (45.9–57.9)
5 57 (47–66) 57.9 (50.9–64.9)
Phases from methanolic extract
 Water 1 13 (7–20) 51.0 (26.6–75.4)
2 5 (2–7) 65.9 (46.7–85.0)
3 8 (0–8) 91.6 (86.2–97.1)
4 115 (76–154) 47.5 (29.8–65.1)
5 76 (59–93) 43.6 (31–56.1)
 Ethylacetate 1 11 (10–13) 58.3 (52.0–64.7)
2 4 (2–5) 73.2 (60.5–85.8)
3 20 (15–25) 79.1 (73.7–84.5)
4 76 (40–112) 65.4 (49.0–81.9)
5 48 (37–59) 64.1 (55.9–72.3)
 Butanol 1 1 (0–3) 95.1 (88.7–100)
2 1 (1–2) 90.2 (85.5–95.0)
3 2 (1–4) 97.6 (95.8–99.4)
4 15 (7–22) 93.3 (89.9–96.7)
5 18 (14–23) 86.4 (82.9–89.9)
Solvent control (0.2% DMSO) 1 27 (22–33)
2 14 (9–19)
3 96 (85–106)
4 219 (198–240)
5 135 (111–158)
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Table 5 Inhibitory activity of  ethylacetate phase fractions from  Vernonia amygdalina leaves against  early sporogonic 
stages
Fractions from ethylacetate phase were tested at 50 µg/mL concentration.
Data are presented as mean early sporogonic stages (ESS) counts calculated from triplicate wells and percentages of ESS inhibition referred to solvent control. Both 
parameters are presented with 95% confidence intervals (95% CI.)
a Each number represents one experiment conducted with gametocytaemic blood from a different mouse.
b Mean ESS counts are rounded to the nearest whole number.
Test agents Experimenta Mean ESS counts (95% CI)b Percentage inhibition of ESS (95% CI)
Fraction‑2 1 27 (17–37) 0.7 (0–38.2)
3 80 (70–90) 16.0 (5.7–26.4)
4 221 (159–281) 0 (0–27.5)
Fraction‑3 1 27 (20–33) 2.0 (0–25.6)
3 93 (77–109) 2.8 (0–19.8)
4 186 (128–245) 14.9 (0–41.7)
Fraction‑5 1 29 (25–33) 0.0 (0–6.8)
3 40 (25–56) 57.8 (42.0–73.7)
4 215 (149–281) 1.8 (0–32.1)
Fraction‑7 1 23 (13–33) 15.4 (0–51.0)
3 98 (84–113) 0 (0–12.2)
4 224 (211–238) 0 (0–3.7)
Fraction‑9 1 31 (19–42) 0.0 (0–29.7)
3 57 (51–63) 40.4 (34.2–46.7)
4 195 (160–229) 11.1 (0–26.8)
Fraction‑10 1 19 (10–27) 31.4 (0–63.7)
2 6 (4–8) 56.1 (26.2–86.0)
3 71 (57–84) 26.3 (12.5–40.1)
4 187 (161–213) 14.8 (3.0–26.6)
Fraction‑11 1 1 (0–2) 96.3 (92.2–100)
2 0 100
3 0 (0–1) 99.7 (99–100)
4 1 (0–1) 99.7 (99.4–100)
5 0 100
Fraction‑12 1 0 100
2 1 (0–2) 95.1 (85.6–100)
3 0 (0–1) 99.7 (99–100)
4 1 (0–2) 99.7 (99.1–100)
5 0 (0–1) 99.8 (99.3–100)
Fraction‑13 1 0 100
2 0 (0–1) 97.6 (92.8–100)
3 0 100
4 0 (0–1) 99.8 (99.5–100)
5 1 (0–2) 99.5 (98.5–100)
Fraction‑14 1 0 100
2 1 (0–2) 92.7 (84.4–100)
3 0 100
4 0 100
5 0 100
Solvent control (0.2% DMSO) 1 27 (22–33)
2 14 (9–19)
3 96 (85–106)
4 219 (198–240)
5 135 (111–158)
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experiments conducted with vernodalol allowed to deter-
mine an IC50 value of 18.7  µM (95% CI 16.1–21.7  µM). 
Evaluating numbers of zygotes and ookinetes separately, 
the proportion of zygotes initiating elongation or devel-
oping to banana shaped mature ookinetes did not appear 
to be affected by vernolide, vernodalol or the fractions 
rich in the two molecules (Additional file  1: Table S1, 
Additional file 2: Table S2).
Effect of vernodalol and ethanolic Vernonia amygdalina 
leaf extract on microgamete formation
Vernodalol and Ver-EtOH were tested in the exflagella-
tion assay to assess whether the effect observed on early 
sporogonic development in the ODA was due to a spe-
cific action on microgametogenesis. Vernodalol tested 
at 50  μM and Ver-EtOH at 50  μg/mL demonstrated 
high inhibitory activity on ESS (Tables 5, 8), but did not 
influence microgamete formation. Similar numbers of 
exflagellation centres per 1,000 RBCs were observed, 
namely 5.5 (95% CI 4–7), 4.8 (95% CI 0–11) and 4.6 (95% 
CI 2.3–6.8), for the solvent control, vernodalol (50 μM) 
and Ver-EtOH (50 μg/mL), respectively. For comparison, 
exflagellation centres counts for azadirachtin A used as 
a positive control in the assay at 50 μM amounted 0.29 
(95% CI 0–0.67).
Cytotoxicity of Vernonia amygdalina extracts, fractions 
and isolated compounds
Ver-EtOH and Ver-MeOH demonstrated a relatively 
higher cytotoxic effect compared with Ver-H2O. Frac-
tions active against ESS development, in particular the 
vernolide-rich fraction 11 and 12, showed strong growth 
inhibitory effects on both cell lines, HCT116 and EA.hy 
926 (Table 8). The selective index (SI) values (ratio of the 
50% inhibitory concentration of mammalian cell viability 
and of ESS growth) of Ver-EtOH (9.46 μg/mL:15.4  μg/
mL) and vernodalol (7.1 µM:18.7 µM) were found to be 
less than one.
Discussion
Exploratory in  vivo studies conducted with P. berghei 
ANKA strain and An. stephensi mosquitoes revealed 
transmission blocking activity of V. amygdalina aque-
ous (Ver-H2O) and ethanolic (Ver-EtOH) leaf extracts. 
Anopheles stephensi females, fed on gametocytaemic 
mice treated with Ver-H2O at 500 mg/kg and Ver-EtOH 
at 100  mg/kg, developed respectively 55 and 90% fewer 
oocysts compared to controls. Subsequent fractionation 
studies, guided by in vitro assays, revealed activity against 
the early stages of sporogonic development in four frac-
tions of the ethylacetate phase. Chemical analysis allowed 
isolation and identification of the two compounds most 
likely responsible for the transmission blocking activity 
observed, namely vernodalol and vernolide. These two 
molecules are sesquiterpene lactones belonging to the 
structural classes of germacranolides (vernolide) and ele-
manolides (vernodalol).
Tested as isolated pure compounds, vernodalol and ver-
nolide exhibited moderate to low activity in the in vitro 
ookinete development assay (ODA). At a concentration 
of 50 μM (19.6 μg/mL) vernodalol inhibited early sporo-
gonic development (ESS) by 70–90%, while vernolide at 
the same concentration (50  μM, 18.1  μg/mL) reduced 
ESS by 9–33%. In line with these data, V.  amygdalina 
Table 6 Transmission blocking activity of ethylacetate fractions from Vernonia amygdalina leaves on Plasmodium falcipa-
rum isolates
Fisher’s exact test was used to compare the proportion of infected mosquitoes between control and treatment groups.
a Oocyst density was calculated considering infected mosquitoes only. *P < 0.05 with respect to the solvent control (dimethyl sulfoxide). Fractions were tested at 100 
µg/mL.
Blood sample Gametocytes  
per µL blood
Treatment % Prevalence of infected  
mosquitoes (infected/total examined)
Oocyst densitya 
(95% CI)
1 160 Solvent control 42.2 (19/45) 4.2 (2.7–6.6)
Fraction‑11 5.1 (2/39)* 2.4 (1.6–3.6)
Fraction‑13 8.3 (3/36)* 1.8 (0.6–5.9)
Fraction‑14 26.2 (11/42) 3.5 (2.3–5.5)
2 184 Solvent control 29.6 (13/44) 3.6 (1.7–5.5)
Fraction‑11 32.4 (12/37) 1.8 (0.3–3.3)
Fraction‑13 6.5 (3/46)* 1.3 (0–2.8)
Fraction‑14 6.7 (3/45)* 1.3 (0–2.8)
3 80 Solvent control 50 (23/46) 3.5 (2.2–5.4)
Fraction‑11 0 (0/36)* –
Fraction‑13 0 (0/27)* –
Fraction‑14 7.3 (3/41)* 1
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EtOAc fractions composed of almost only vernodalol and 
vernolide showed evident inhibitory activity in the ODA. 
Fraction 11 (about 91% vernolide), fraction 12 (about 
50% vernolide + 50% vernodalol) and fraction 13 (about 
85% vernodalol) suppressed ESS by 95–100% when tested 
at 50 μg/mL (corresponding to amounts of 42–50 μg/mL 
of vernolide, vernodalol or vernolide + vernodalol).
A relatively stronger activity than expected for its ver-
nodalol and vernolide content, was observed with the 
EtOAc phase preparation. At 50 μg/mL, corresponding 
to 2.04  μg/mL vernolide and 2.16  μg/mL vernodalol 
equivalents, the preparation inhibited ESS by 60–80%. 
This finding may indicate the presence of other bioac-
tive constituents in the EtOAc phase, having a direct 
effect on ESS or modulating the activity of vernolide 
and vernodalol. The same interpretation may hold for 
the results obtained with Ver-EtOH, which was found 
to inhibit ESS by 80–95% at 50  μg/mL but contained 
vernolide and vernodalol at a low concentration of 0.84 
and 0.89  μg/mL, respectively. Differential counting of 
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Fig. 6 Impact of organic solvent fractions from Vernonia amygdalina leaves (100 µg/mL) on sporogonic development. Mosquitoes were membrane 
fed on blood from three donors with Plasmodium falciparum gametocytaemia values of: a 160 gametocytes/μL, b 184 gametocytes/μL and c 80 
gametocytes/μL. Each point represents the oocyst number from an individual mosquito. In a the data point of one midgut on which 94 oocysts 
were recorded, is not plotted in the graph (largely out of scale).
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zygotes and ookinetes indicated that Ver-EtOH inter-
fered with processes preceding zygote formation. At 
the highest tested concentration (50 μg/mL), however, 
an impact on subsequent ookinete maturation was also 
observed. Interestingly, this was not the case with pure 
vernolide and vernodalol or with fractions 11 to 13, 
consisting almost entirely of these two compounds, an 
observation suggesting that the two sesquiterpene lac-
tones may interfere with the first processes of sporo-
gonic development, namely gametogenesis and/or 
macrogamete fertilization.
Exflagellation tests performed with vernodalol and 
Ver-EtOH allowed to further narrow down the possible 
target stages. Both the compound and the extract, tested 
at 50  μM and 50  μg/mL respectively, did not interfere 
with microgamete formation in vitro, suggesting that the 
processes targeted by V. amygdalina transmission block-
ing components are mainly macrogametogenesis and/or 
macrogamete fertilization.
Vernolide and vernodalol have been reported to exhibit 
moderate activity also on asexual blood stages (39, 40), 
inhibiting P. falciparum asexual forms by 50% at a con-
centration of 1.87–8.4 and 4.2  μM, respectively. This 
multi-stage activity of vernodalol and vernolide raises 
exciting questions on modes and mechanisms of action 
of the two sesquiterpene lactones and research focused 
into this aspect may lead to the discovery of novel multi-
stage drug targets.
In our exploratory in vivo transmission blocking exper-
iment, Ver-EtOH was found to reduce the prevalence of 
infection in mosquitoes fed on gametocytaemic mice 
treated (i.p.) with the extract at 100 mg/kg by about 30%, 
and oocyst density by 90%. Taking into account the rela-
tive amount of vernolide and vernodalol in Ver-EtOH, at 
the tested extract dosage mice received approximately 
1.7  mg/kg vernolide and about 1.8  mg/kg vernodalol. 
Given this relatively low doses of the transmission block-
ing compounds, other bioactive molecules in the extract 
are likely to have contributed directly or indirectly to 
the transmission blocking effect, as discussed also above 
relating to Ver-EtOH activity on early sporogonic devel-
opment in vitro.
The experiments conducted in Burkina Faso with P. fal-
ciparum field isolates allowed us to evidence the trans-
mission blocking activity of V. amygdalina also against 
the human malaria parasite. An. coluzzii mosquitoes that 
had membrane-fed on gametocytaemic blood treated 
Table 7 Impact of vernolide and vernodalol on the development of early sporogonic stages in vitro
Compounds were tested at a concentration of 50 μM.
a Each number represents one experiment conducted with gametocytaemic blood from a different mouse; ESS counts are means from sextuplicate wells.
b Mean ESS counts are rounded to the nearest whole numbers.
Test compounds Experimenta Mean ESS  
counts (95% CI)b
Percentage inhibition 
of ESS (95% CI)
Vernodalol 1 24 (21–26) 79.3 (77.3–81.4)
2 12 (8–16) 89.7 (86.4–92.9)
3 92 (77–107) 69.3 (64.3–74.3)
Vernolide 1 103 (90–115) 9.4 (0–20.5)
2 79 (63–95) 30.6 (16.7–44.5)
3 201 (182–220) 33 (26.6–39.3)
Solvent control (0.2% DMSO) 1 113 (93–134)
2 114 (97–132)
3 300 (284–317)
Table 8 Activity of Vernonia amygdalina extracts, fractions 
and  pure compounds on  cell viability of  a human colon 
cancer and endothelial cell line
Each value represents the mean of two experiments carried out in quadruplet 
wells.
Ver-EtOH, Ver-MeOH, and Ver-H2O stands for ethanolic, methanolic and aqueous 
extract of V. amygdalina leaves.
HCT 116 human colon carcinoma cell line, EA.hy 926 human (non-tumour) 
endothelial cell line, 95% CI 95% confidence interval.
Test agents IC50 (95% CI)
HCT116 EA.hy 926
Leaf extracts (μg/mL)
 Ver‑EtOH 3.66 (3.41–3.96) 9.46 (8.64–10.36)
 Ver‑MeOH 8.09 (7.54–8.67) 16.94 (15.55–18.46)
 Ver‑H2O 64.34 (58.75–70.53) 76.21 (58.09–100.00)
Fractions from methanol extract (μg/mL)
 Fraction 11 0.17 (0.15–0.18) 0.42 (0.39–0.45)
 Fraction 12 0.33 (0.3–0.37) 1.13 (0.97–1.31)
 Fraction 13 2.41 (2.29–2.53) 4.52 (4.23–4.82)
 Fraction 14 3.86 (3.62–4.12) 7.69 (7.10–8.32)
Molecules from fractions (μM)
 Vernolide 1.49 (1.38–1.61) 3.18 (2.97–3.4)
 Vernodalol 4.97 (4.78–5.17) 7.1 (6.51–7.74)
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with the vernolide and vernodalol-rich EtOAc fractions 
(fraction 11 and 13, respectively) were less infected and 
oocyst numbers in positive mosquitoes were reduced by 
about half. The membrane feeds were supplemented with 
the fractions at a dosage of 100 μg/mL corresponding to 
vernolide and vernodalol equivalents of 91.2 and 85 μg/
mL, respectively. The relatively high dosage needed to 
achieve a substantial reduction in sporogonic develop-
ment of P. falciparum, taken together with the moder-
ate activity by the pure compounds observed in vitro on 
P. berghei, suggest that neither vernodalol nor vernolide 
possess the potency required for a drug candidate mol-
ecule. On the other hand, significant transmission block-
ing activity by the Ver-EtOH was evidenced from the 
in  vivo experiments; and the bio-guided fractionation 
studies revealed a relatively higher in  vitro activity of 
extracts compared to that of the pure compounds, sug-
gesting that the development of a phytomedicine based 
on vernodalol and vernolide enriched standardized 
extract may be a more appropriate strategy to pursue.
Artemisinin derivatives have been demonstrated 
to possess activity against P. falciparum gametocytes 
in  vitro [63] and in clinical trials [3], shortening the 
period of gametocytes circulation in patients treated 
with ACT [64] and thus decreasing the infection rates of 
blood seeking mosquitoes. In the current in  vivo study, 
Ver-H2O administered to mice at 500  mg/kg was found 
to reduce macrogametocyte densities by about 50%. A 
decrease in microgametocyte numbers was also noticed, 
reaching significance in one of the two replicates car-
ried out. Since Ver-H2O did not exhibit in vitro activity 
on ESS, but still reduced oocyst densities in mosquitoes 
when administered to females in vivo through an infec-
tious blood meal, the observed transmission blocking 
effect might be attributed to the gametocytocidal activity 
of Ver-H2O.
Considering the diverging gametocyte biology of P. fal-
ciparum and P. berghei [65], a validation of the extract’s 
activity on P. falciparum gametocytes is the next step 
to be undertaken. If confirmed, subsequent bio-guided 
fractionation studies may allow the identification of new 
gametocytocidal compounds.
Vernonia amygdalina leaves have been the object of 
various studies evidencing the presence of bio-active 
secondary metabolites belonging to the classes of sapo-
nin, flavonoid, alkaloid, tannin, terpenes, phytosteroids 
[66–69]. From a comparative study on the profile of V. 
amygdalina secondary metabolites of an aqueous and an 
ethanol extract emerged an abundant presence of polar 
polyphenols in the former [70]. This feature has been 
confirmed by other chemical investigations on Ver-H2O 
extracts [67, 68]. In the present study, sesquiterpene lac-
tones, namely vernolide and vernodalol, were identified 
in the less polar phase of Ver-MeOH extract. Considering 
the similar polarity index of ethanol and methanol [71], it 
seems correct to assume that Ver-EtOH used in the pre-
sent study contains sesquiterpene lactones as well. On 
the contrary, given their poor water solubility, it is very 
unlikely that sesquiterpene lactones can be present in 
Ver-H2O [72], thus providing chemical bases to the dif-
ference in biological responses between Ver-EtOH and 
Ver-H2O.
The cytotoxic properties of V. amygdalina extracts 
and compounds have been assessed on various cell lines: 
IC50 values vary widely with the compounds and type of 
cell lines used. For instance, a value of 0.11 μg/mL was 
estimated for vernolide against leukemia cells [73] and 
70–75  μg/mL for vernodalinol against human breast 
carcinoma cells [33]. Studies assessing in  vitro anti-
plasmodial and cytotoxic activity estimated SI values in 
the range of 5–10 for ethanol and hydroethanol extracts 
[74, 75], while for a chloroform extract, an SI value of 
less than one was reported [76]. Pedersen and colleagues 
determined vernodalol IC50 value against P. falciparum 
blood stages and on a Chinese hamster ovarian cell line of 
3.8 and 26.4 μg/mL, respectively, implying an SI value of 
seven [77]. In the present study, both, Ver-EtOH and ver-
nodalol, were found to exhibit SI value below one. Refer-
ring to the antiplasmodial drug development consensus, 
a hit compound should display an SI value of at least ten 
(a tenfold higher activity against parasites than against a 
mammalian cell line) to be considered for further devel-
opment [78]. However, given the interesting multi-stage 
activity of vernodalol and vernolide, the molecules still 
are worth to be considered for structure–activity rela-
tionship studies aimed at designing compounds with 
reduced toxicity and enhanced activity against ESS and 
asexual blood stage parasites. Also, the compounds 
might be utilized as tools to investigate potential drug 
targets expressed in multiple life cycle stages.
From studies aimed at elucidating the effects of ver-
nolide on the immune response of melanoma-bearing 
mice and vernodalin (a sesquiterpene related to vernod-
alol) on antischistosomal activity in cercaria-infected 
mice, no serious adverse effect was observed in the ani-
mals after administration of vernolide at the immune 
modulatory dose of 0.5 mg/kg i.p. [79] and vernodalin at 
antischistosomal dose of 2.5 mg p.o [40]. In the present 
study, mice were treated with Ver-EtOH at 100  mg/kg 
[vernolide 1.68  mg/kg +  vernodalol 1.78  mg/kg equiva-
lent dose] i.p. twice and 500 mg/kg [vernolide 8.4 mg/kg 
and vernodalol 8.9 mg/kg equivalent dose] p.o. for 9 days 
in the in  vivo efficacy experiments. At these doses the 
extracts appeared tolerable, with no visible signs of toxic 
effects on the mice. Information on the median lethal 
dose (LD50) of Ver-EtOH and Ver-H2O in rodents is also 
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available from various studies: LD50 estimates of Ver-
EtOH range from 288 mg/kg (i.p.) in mice to 1,950 mg/kg 
(p.o.) in rats whereas those for Ver-H2O from 560 mg/kg 
(i.p.) in mice to 3,320 mg/kg (p.o.) in rats [30, 80–84]. A 
sub-acute toxicity evaluation of Ver-H2O in rats showed 
that the extract did not cause any life-threatening adverse 
effect up to the dose of 2,000 mg/kg (p.o.) though at a dos-
age of 1,000 mg/kg a decrease RBC counts, an increased 
level of bilirubin and uric acid had been recorded [30]. In 
a sub-chronic toxicity study of an organic solvent frac-
tion from Ver-MeOH (up to 320 mg/kg, p.o.), no clinical 
chemistry and histological abnormalities in vital organs 
were observed in rats [85]. These results are in agreement 
with our observations on the tolerability of V.  amygda-
lina extracts at the doses administered to mice in the 
current study for the evaluation of in  vivo transmission 
blocking activity of Ver-EtOH (100 mg/kg i.p. once daily 
for 2 days) and the gametocytocidal evaluation (250 mg/
kg p.o. twice daily for 9 days).
Conclusions
Previously published work and findings from the pre-
sent study demonstrate that V.  amygdalina leaves con-
tain molecules affecting multiple stages of Plasmodium, 
evidencing its potential for drug discovery and for the 
development of standardized V.  amygdalina-based phy-
tomedicines. On the identified hit molecules, primarily 
vernodalol, chemical modification is recommended to 
generate a druggable compound with enhanced activity 
against the blood and sporogonic stages of the malaria 
parasite and reduced off-target activities. In addition, 
based on the findings presented here, the development of 
a multistage phytomedicine, exhibiting both anti-blood 
stage as well as transmission blocking properties and 
designed as a preventive treatment to complement exist-
ing malaria control tools appears a challenging but feasi-
ble goal.
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